Neuraxis, Inc.
NRXS Healthcare Biotechnology
Neuraxis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 115.7%, EPS grew 13.6% and free cash flow grew 29.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow NRXS
Neuraxis, Inc. (NRXS) EV/Sales
As of 16 October 2026, Neuraxis, Inc. (NRXS) trades at a EV/Sales of 16.0×. Over the past ten years it has ranged from 2.4× (October 2023) to 20.9× (May 2026); the current reading is higher than 92% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.2× | 116.84% |
| FY2024 | 4.7× | 40.39% |
| FY2023 | 3.3× | (25.33%) |
| FY2022 | 4.5× | 0.00% |
| FY2021 | 4.5× | 0.00% |
| FY2020 | 4.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 15.1× | (12.56%) |
| Mar 2026 | 17.3× | 69.83% |
| Dec 2025 | 10.2× | 31.13% |
| Sep 2025 | 7.8× | 70.16% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MIST Milestone Pharmaceuticals Inc. compare | −2.4× |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| ICCC ImmuCell Corporation compare | 3.1× |
| NRXS Neuraxis, Inc. | 16.0× |
| CBUS Cibus, Inc. compare | 18.9× |
| ATRA Atara Biotherapeutics, Inc. compare | 20.7× |
| ANIX ANIXA BIOSCIENCES INC compare | 83.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)